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Background:  In  recent  years,  the  renewed  global  interest  in  both  hallucinogens’  and  
cannabis’  therapeutic  properties  has  resulted  in  shifting  attitudes  and  legislative  policies  
worldwide.  The  aim  of  this  systematic  review  is  to  explore  the  existing  literature  on  medical  
professionals’  and  students’  attitudes  and  knowledge  regarding  medicinal  cannabis  (MC)  to  
assess  any  relevant  and  significant  trends  which  may  forecast  analogous  trends  in  the  
nascent  clinical  acceptance  of  hallucinogens.    
Methods:  Using  Google  Scholar  and  PubMed,  a  literature  search  was  performed  to  identify  
studies  pertaining  to  healthcare  professionals’  and  medical  students’  knowledge  and  
attitudes  regarding  MC.  This  systematic  search  yielded  43  studies  published  between  1971  
and  2019;  inclusion  criteria  included  the  following:  1)  the  studies  were  complete  and  not  
simply  abstracts  or  systematic  reviews;  2)  they  provided  relevant  data  regarding  
respondents’  knowledge  and  attitudes  regarding  MC;  3)  they  were  published  in  English  and  
originated  in  a  country  with  a  healthcare  system  and  legislative  policies  comparable  to  that  
of  the  USA;  and  4)  they  contained  medical  professional  (or  student)  respondents  only;  or,  if  
the  respondents  included  mixed  groups,  the  study  segregated  and  sorted  data  based  on  
one’s  status  as  a  medical  professional  or  non-­‐medical  professional.  Studies  were  then  coded  
according  to  the  following  five  guiding  research  questions:  1)  Do  respondents  believe  that  
cannabis  should  be  legalized  for  medicinal  purposes,  and  have  these  opinions  changed  
significantly  over  time?;  2)  Are  respondents  confident  in  their  level  of  knowledge  regarding  
cannabis’  health  effects  and  clinical  applications?;  3)  Are  respondents  adequately  convinced  
of  cannabis’  therapeutic  potential?  What  are  respondents’  main  concerns  regarding  the  
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incorporation  of  cannabis  into  the  medical  system?;  4)  What  current  gaps  in  knowledge  
exist,  and  how  can  the  medical  community  become  better  informed  about  the  therapeutic  
uses  of  cannabis?;  and  5)  Are  there  significant  differences  between  the  knowledge  and  
opinions  of  healthcare  students’  versus  healthcare  professionals’  with  respect  to  any  of  the  
aforementioned  research  questions?  
Results:  At  a  multi-­‐national  level  (from  1990  to  present),  both  medical  students’  and  
professionals’  support  for  the  legalization  of  MC  has  significantly  increased  (r(19)  =  .44,  p  =  
.045).  Moreover,  medical  professionals  favor  the  legalization  of  MC  at  a  significantly  higher  
rate  than  students  (52%  vs.  42%,  respectively;  χ2  (1,  N  =  9019)  =  50.72  p  <  .001).  
Furthermore,  an  assessment  of  both  respondents’  desire  for  more  educational  material  on  
MC  and  respondents’  concerns  regarding  MC’s  potential  to  cause  dependence  and  
addiction  showed  a  ceiling  effect,  with  respondents  consistently  reporting  high  levels  of  
desire  for  more  educational  material  and  a  high  level  of  concern  regarding  MC’s  addictive  
potential,  but  with  no  significant  changes  over  time  (r(13)  =  -­‐.10,  p  =  .713  &  r(11)  =  -­‐.13,  p  =  
.673,  respectively).    
Discussion:  This  systematic  review  yielded  several  statistically-­‐significant  trends  pertaining  
to  healthcare  professionals’  and  medical  students’  knowledge  and  attitudes  about  MC.  As  
MC  use  and  legalization  continues  to  proliferate  internationally,  further  studies  are  needed  
to  elucidate  complex  sociocultural  barriers  to  the  acceptance  of  MC,  which  are  likely  to  be  
closely  correlated  with  barriers  to  the  clinical  acceptance  of  therapeutic  hallucinogens.  
Limitations,  cross-­‐cultural  mechanisms,  clinical  implications,  and  recommendations  for  




Hallucinogens  are  a  broad  class  of  pharmacological  compounds  which  reliably  and  
temporarily  induce  profound  sensory  distortions  and  shifts  in  cognition.  The  three  main  
families  of  hallucinogenic  drugs  are:  serotonergic  (i.e.  “classical”)  psychedelics,  such  as  
psilocybin  (the  main  psychoactive  compound  in  hallucinogenic  mushrooms),  LSD,  MDMA,  
and  DMT  (the  active  ingredient  in  the  shamanic,  Amazonian  brew  ayahuasca);  dissociative  
anesthetics,  e.g.  ketamine,  PCP,  and  dextromethorphan  (DXM);  and  deliriants,  which  are  
principally  found  in  members  of  the  Solanaceae  (nightshade)  family  of  plants.  Additionally,  
some  researchers  consider  cannabis  and  its  derivatives  medicinal  hallucinogens,  and  
ethnographic  anthropological  research  has  also  demonstrated  that  the  ingestion  of  certain  
animals  and  their  associated  products  (i.e.  venom,  glandular  secretions,  etc.)  have  been  
used  by  various  indigenous  cultures  as  a  form  of  ritualistic  hallucinogen  use  (Groark,  1996).    
   The  western  medical  community  started  appropriating  hallucinogens  as  a  powerful  
psychiatric  tool  in  the  early  20th  century,  as  advances  in  chemistry  allowed  for  the  extraction  
and  chemical  isolation  of  these  compounds  from  their  organic  sources.  Initially,  western  
clinicians  were  bewildered  by  the  profound  psychoactive  effects  of  hallucinogens,  and  
consequently  labeled  them  “psychotomimetics”–  substances  which  can  reliably  replicate  
psychosis  and  other  abnormal  psychological  states  (Mangini,  1998).  Continued  research  also  
revealed  that  these  compounds  produced  “a  lowering  of  inhibitions  in  patients  undergoing  
psychoanalysis,”  leading  to  “particularly  vivid  and  intense  awareness  of  personality  
problems”  (Rochester  &  Kirchner,  1999;  Mangini,  1998).  Clinicians  soon  realized  that  
hallucinogens  could  have  widespread  psychiatric  applications  in  the  treatment  of  various  
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personality,  mood,  and  behavioral  disorders.  Throughout  the  mid  20th  century,  psychiatrists  
adapted  hallucinogen-­‐based  therapies  to  treat  a  variety  of  conditions,  including:  addiction,  
(treatment-­‐resistant)  depression,  anxiety  associated  with  terminal  illness,  and  post-­‐
traumatic  stress  disorder  (PTSD)  (Byock,  2018).  Despite  researchers’  extensive  findings  
supporting  the  general  safety  and  efficacy  of  hallucinogen-­‐assisted  psychotherapies,  
international  legislation  swiftly  imposed  a  sweeping  prohibition  on  all  hallucinogen  
possession,  use,  and  research  in  1971  after  reports  surfaced  of  widespread  unethical  
research  practices  amongst  a  large  subset  of  clinicians.  Moreover,  the  international  
geopolitical  and  social  atmosphere  at  the  time  reflected  a  strong  schism  between  
conservative  values  and  progressive  ideals,  and  many  right-­‐leaning  politicians  worried  that  
the  proliferation  of  hallucinogens  would  further  disrupt  the  global  geopolitical  order.  
Consequently,  biomedical  research  into  hallucinogens  stalled  for  the  remainder  of  the  20th  
century,  and  only  recently  have  investigators  begun  petitioning  governments  for  permits  to  
resume  studies.  
   In  several  cases  in  various  countries,  exemptions  have  been  made  for  the  use  of  
psychedelics  as  part  of  religious  practices.  In  1993,  the  Unites  States  passed  official  
legislation  stating  that  drug  laws  may  be  trumped  by  the  right  to  freely  practice  religion,  in  
accordance  with  the  Religious  Freedom  Restoration  Act  (Elsey,  2017).  Nevertheless,  legal  
interpretation  over  what  constitutes  “religious  practices”  continues  to  limit  citizens’  access  
to  hallucinogens  (Labate  &  Feeney,  2012).  As  of  May  2019,  the  city  of  Denver,  Colorado  
became  the  first  American  municipality  to  decriminalize  adult  recreational  use  of  psilocybin  
(Foody,  2019).  However,  as  some  governments  move  toward  deregulation  and  renewed  
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scientific  research,  others  continue  to  enact  strongly  oppositional  legislation,  highlighting  
the  current  ignorance,  confusion,  and  misinformation  still  enshrouding  hallucinogens.  To  
combat  the  growing  “research  chemical”  phenomenon,  whereby  clandestine  chemists  
synthesize  novel  chemical  analogs  of  regulated  hallucinogens  to  evade  legal  prosecution,  
the  UK  parliament  passed  the  Psychoactive  Substances  Act  in  2016,  designed  to  stop  the  
proliferation  of  these  novel  compounds  (Elsey,  2017).  Most  notably,  the  bill  levies  a  strict  
prohibition  on  all  hallucinogenic-­‐derivatives  and  sidesteps  the  need  to  demonstrate  any  
potential  for  harm,  which  further  hampers  researchers’  ability  to  reopen  investigations  into  
the  therapeutic  potential  of  hallucinogens.  
The  United  States  Drug  Enforcement  Administration  (DEA)  currently  sorts  drugs,  
substances,  and  certain  chemicals  used  to  make  drugs  into  five  distinct  categories—i.e.  
schedules—depending  upon  the  drug’s  acceptable  medical  use  and  the  drug’s  abuse  or  
dependency  potential  (Drug  Enforcement  Administration  [DEA],  n.d.).  Although  
investigations  into  Schedule  1  (the  most  restrictive  classification,  asserting  that  the  
substance  has  no  accepted  medical  use)  hallucinogens  (primarily  the  serotonergic,  
psychedelic  class)  remain  severely  limited  in  the  US,  researchers  have  made  use  of  
somewhat  atypical  hallucinogens  that  fall  into  less  stringent  schedules.  Ketamine—a  
dissociative  hallucinogen—is  currently  listed  under  the  Schedule  III  category  due  to  its  
principal  use  as  a  general  anesthetic  at  high  doses.  Researchers  who  recognized  its  latent  
psychiatric  benefits  began  conducting  off-­‐label  trials  in  patients  suffering  from  severe  
treatment-­‐resistant  depression  (TRD).  As  a  result,  the  FDA  recently  has  approved  limited  
clinical  trials  of  ketamine  for  TRD,  and  the  Russian  government  has  also  extensively  
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supported  the  use  of  ketamine  to  treat  various  addiction-­‐related  disorders  (Winkelman  &  
Roberts,  2007).  FDA-­‐approved  studies  of  ketamine  have  now  reached  Phase  IV–  meaning  
multicenter,  randomized,  double-­‐blind  investigations  involving  thousands  of  participants  
are  now  underway  (Winkelman  &  Roberts,  2007).    
   The  history  of  cannabis  in  medicine  is  highly  analogous  to  that  of  classical  
hallucinogens.  Archaeological  inquiry  has  revealed  that  cannabis  use  has  been  prevalent  in  
human  society  for  at  least  five  millennia,  and  it  was  even  widely  used  as  a  medical  therapy  
in  the  United  States  in  the  19th  and  early  20th  centuries;  in  fact,  it  was  first  included  in  the  
United  States  Pharmacopoeia  in  1850  (Bridgeman  &  Abazia,  2017).  The  first  federal  
restrictions  on  cannabis  occurred  in  1937,  with  the  passage  of  the  Marihuana  Tax  Act,  which  
heavily  regulated  its  sale  and  usage.  Subsequently,  cannabis  was  dropped  from  the  United  
States  Pharmacopoeia  in  1942,  and  legal  penalties  for  its  possession  increased  in  1951  and  
1956  with  the  enactment  of  the  Boggs  and  Narcotic  Control  Acts,  respectively.  Finally,  the  
Controlled  Substances  Act  of  1970  relegated  cannabis  to  schedule  I  status  at  the  federal  
level,  imposing  limitations  on  research  by  restricting  the  procurement  of  cannabis  for  
academic  purposes  (Bridgeman  &  Abazia,  2017).  Moreover,  cannabis  remains  illegal  under  
international  law,  as  outlined  in  the  United  Nations’  Single  Convention  on  Narcotic  Drugs  
(1961),  which  places  cannabis  and  its  derivative  products  in  Class  IV  –  the  most  restrictive  
category,  analogous  to  the  DEA’s  Schedule  I  designation.    
Notwithstanding,  33  U.S.  states  and  several  dozen  nations  across  the  globe  have  
passed  laws  permitting  the  renewed  medicinal  use  of  cannabis  in  recent  years  and  decades  
(Hanson  &  Garcia,  2019;  Bifulco  &  Pisanti,  2015).  Therefore,  an  assessment  of  the  ongoing  
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trends  surrounding  the  reintegration  of  cannabis  into  accepted  medical  practice  provides  
insight  into  how  the  medical  community  may  reinvestigate  formerly  prohibited  and  
stigmatized  therapies–  including  hallucinogens.  Fortunately,  dozens  of  studies  regarding  
clinicians’,  patients’,  medical  students’,  and  public  health  professionals’  attitudes  and  
knowledge  regarding  medicinal  cannabis  (MC)  have  been  published  in  recent  decades.  
Several  of  these  studies  predate  the  first  legislative  bill  legalizing  medicinal  cannabis  in  
California  (in  1996),  and  many  studies  were  conducted  between  1996  and  2019–  when  32  
other  states  and  several  countries—including  Canada,  Australia,  and  Israel—legalized  
cannabis  for  therapeutic  purposes  (Bridgeman  &  Abazia,  2017;  Hanson  &  Garcia,  2019;  
Fischer,  Kuganeson,  &  Room,  2014;  Thomsen,  2016;  Kloosterman,  Blum,  Leichman,  &  Barak,  
2015).  Data  from  these  studies  can  be  analyzed  along  several  categorical  and  temporal  
parameters  to  elucidate  specific  trends  regarding  the  medical  community’s  overall  attitudes  
and  opinions  regarding  the  clinical  reintroduction  of  MC,  which  helps  reveal  ways  in  which  
the  medical  community  can  improve  its  acceptance  of  novel  hallucinogenic  therapies  in  the  
future.  When  assessing  the  content  of  these  studies,  some  central,  guiding  research  
questions  included  the  following:    
1.   Do  healthcare  students  and  professionals  believe  that  cannabis  should  be  
legalized  for  medicinal  purposes?  Have  these  opinions  changed  significantly  
over  time?  
  
2.   Are  healthcare  students  and  professionals  confident  in  their  level  of  
knowledge  regarding  cannabis’  health  effects  and  clinical  applications?  
  
3.   Are  healthcare  students  and  professionals  adequately  convinced  of  cannabis’  
therapeutic  utility?  What  are  healthcare  professionals’  main  concerns  
regarding  the  incorporation  of  cannabis  into  the  medical  system?    
  
4.   What  current  gaps  in  knowledge  exist,  and  how  can  the  medical  community  
become  better  informed  about  the  therapeutic  uses  of  cannabis?  
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5.   Are  there  significant  differences  between  the  knowledge  and  opinions  of  
healthcare  students’  versus  healthcare  professionals’  with  respect  to  any  of  
the  aforementioned  research  questions?  
  
Initially,  several  hypotheses  were  developed  in  accordance  with  the  guiding  research  
questions.  Question  1  assessed  respondents’  support  for  the  legalization  of  MC.  It  was  
expected  that  support  for  the  legalization  of  MC  would  increase  over  time  due  to  ongoing  
sociocultural  and  legislative  trends  favoring  legalization,  which  may  serve  to  reduce  stigma  
and  increase  the  normalization  of  cannabis  within  the  medical  community. Question  5  
assessed  differences  between  medical  students  and  medical  professionals  regarding  their  
knowledge  and  opinions  of  MC–  a  consideration  which  applies  to  all  the  guiding  research  
questions.  It  was  expected  that  students  would  demonstrate  greater  support  for  the  
legalization  of  MC  than  medical  professionals,  given  the  premise  that  many  medical  
professionals  may  have  been  educated  during  an  era  in  which  cannabis  was  largely  
demonized  within  society  and  the  medical  community,  and  the  established  research  finding  
that  (at  least  within  the  United  States)  younger  individuals  are  adopting  more  permissive  
views  towards  marijuana  (Schmidt,  Jacobs,  &  Spetz,  2016).  With  respect  to  research  
question  2,  which  assesed  respondents’  self-­‐reported  confidence  regarding  their  knowledge  
of  MC,  it  was  hypothesized  that  confidence  levels  would  rise  as  the  number  of  years  
following  MC  legalization  in  the  country  of  a  study’s  publication  increased,  due  to  
respondents’  from  those  countries  having  an  increased  likelihood  of  being  exposed  to  
cannabis  in  clinical  settings.  Moreover,  it  was  expected  that  professionals  (as  opposed  to  
students)  would  express  greater  confidence  in  their  knowledge  of  MC,  given  their  more  
extensive  medical  training  and  clinical  experience.  Question  3  investigated  respondents’  
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belief  in  cannabis’  medical  utility.  It  was  hypothesized  that  respondents’  from  more  recently  
published  studies  would  espouse  greater  faith  in  cannabis’  medical  utility  due  to  the  
ongoing  proliferation  of  cannabis  within  diverse  clinical  settings.  Additionally,  it  was  
predicted  that  students  would  express  greater  faith  in  cannabis’  medical  utility  under  the  
premise  that  students  (being  younger,  on  average,  than  professionals)  would  be  more  likely  
to  have  been  raised  in  a  sociopolitical  climate  more  accepting  of  cannabis’  medical  
applications.  Finally,  with  respect  to  research  question  4,  which  assessed  current  gaps  in  
knowledge  and  ways  to  improve  knowledge  of  MC  within  the  medical  community,  it  was  
expected  that  respondents  from  more  recent  studies  would  express  an  increased  desire  for  
further  education,  given  the  heightened  acceptance  of  cannabis  as  a  legitimate  medical  
therapy  in  recent  years. In  light  of  the  parallel  legislative  hurdles  and  cultural  stigmatization  
surrounding  both  cannabis  and  hallucinogens,  this  systematic  review  will  provide  an  
important  framework  for  better  understanding  how  the  medical  community  can  work  to  





Using  both  Google  Scholar  and  PubMed,  a  literature  search  was  performed  to  
identify  studies  pertaining  to  healthcare  students’  and  professionals’  knowledge  and  
attitudes  regarding  therapeutic  and  non-­‐therapeutic  uses  of  cannabis.  Studies  which  
solicited  the  opinions  of  M.D.’s,  R.N.’s  P.A.’s,  Pharm.D.’s,  and  medical  and  pharmacy  
students  were  all  included  in  the  search.  Most  inquiries  utilized  relevant  keywords,  such  as:  
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“attitudes  on  medical  marijuana”  and  “physicians’  perspectives  on  cannabis,”  etc.  
Additionally,  when  viewing  a  study  on  PubMed  and  Google  Scholar,  both  databases  provide  
the  researcher  with  extensive  lists  of  related  studies–  helping  to  augment  the  simple  
keyword  search  protocol.   
The  literature  search  only  included  English-­‐language  papers,  and  generally  focused  
on  studies  originating  in  the  United  States.  However,  the  search  eventually  expanded  to  
include  international  studies  from  countries  with  generally  similar  healthcare  systems  and  
legislative  policies  towards  (medicinal)  cannabis–  including  Ireland,  Canada,  Israel,  Serbia,  
and  Australia.  While  some  of  these  nations  slightly  differ  from  the  United  States  in  terms  of  
their  national  healthcare  systems  and  legislative  policies  toward  cannabis,  it  was  
determined  that  the  value  gained  from  including  global  perspectives  on  this  issue  was  at  a  
sufficiently  low  cost  to  the  validity  of  the  comparisons  drawn.  Studies  met  criteria  for  
inclusion  if  they  satisfied  all  of  the  following  requirements:  1)  they  were  complete  studies  
and  not  simply  abstracts  or  systematic  reviews;  2)  they  provided  relevant  data  regarding  
one  or  more  of  the  aforementioned  guiding  research  questions;  3)  they  were  published  in  
English  and  originated  in  a  country  with  a  healthcare  system  and  legislative  policies  
(towards  [medicinal]  cannabis)  comparable  to  that  of  the  United  States;  and  4)  they  
contained  medical  professional  (or  student)  respondents  only;  or,  if  the  respondents  
included  mixed  groups  with  non-­‐medical  professionals,  the  study  segregated  and  sorted  
data  based  on  one’s  status  as  a  medical  professional  or  non-­‐medical  professional.  Studies  
were  excluded  from  further  analysis  if  they  failed  to  meet  any  one  of  these  four  specified  
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requirements.  Overall,  43  studies  were  identified  as  meeting  all  the  necessary  criteria  for  
inclusion.    
Data  from  studies  which  met  all  four  inclusion  criteria  were  subsequently  
incorporated  into  a  master  spreadsheet,  which  included  the  following:  last  name  of  the  first  
author  listed  on  the  study;  year  and  country  of  publication;  total  number  of  participants  
included  in  the  study;  the  type(s)  of  participants  featured  in  the  study  (i.e.  oncologists,  RN’s,  
etc.,  and  the  number  of  each  type  of  participant  if  several  were  included  in  the  same  study);  
mean  age  of  the  study  cohort;  percent  breakdown  of  participants  by  gender;  percentage  of  
participants  who  reported  a  Caucasian  ethnicity;  and  mean  number  of  years  in  practice  for  
the  study  cohort.  While  sorting  through  papers  to  extract  data  pertaining  to  the  four  
aforementioned  guiding  research  questions,  it  became  apparent  that  while  most  papers  
addressed  similar  topics,  they  often  phrased  their  questions  in  slightly  different  ways.  For  
example,  Chan,  Knoepke,  Cole,  McKinnon,  and  Matlock  (2016)  asked  respondents  to  either  
agree  or  disagree  with  the  following  statement:  “physicians  should  recommend  marijuana  
as  medical  therapy,”  whereas  other  researchers,  such  as  Ananth  et  al.  (2018)  asked  
respondents  to  state  whether  or  not  they—as  physicians—would  be  willing  to  prescribe  
marijuana  to  a  patient.  Though  these  questions  may  not  be  exactly  analogous,  they  both  
address  the  question  of  whether  or  not  physicians  should  be  allowed  to  authorize  MC.  
Therefore,  it  was  determined  that  both  questions  could  be  analyzed  under  the  same  
category:  in  this  instance,  both  were  filed  under  research  question  1:  “Do  healthcare  
professionals  believe  that  cannabis  should  be  legalized  for  medicinal  purposes?”  Similar  
judgment  calls  were  made  in  numerous  other  instances  when  the  phraseology  of  certain  
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studies  did  not  directly  align  with  the  phraseology  used  in  the  spreadsheet.  Throughout  the  
collection  process,  data  pertaining  to  the  five  guiding  research  questions  were  further  
subdivided  into  seven  specific  research  questions;  a  full  layout  of  the  phraseological  sorting  
process—in  accordance  with  the  seven  derived  research  questions  tabulated  in  the  master  
spreadsheet—is  provided  below:   
 
Analysis  and  sorting  by  research  question  phraseology:    
  
•   Research  question  1:  Do  you  believe  that  physicians  deserve  the  legal  right  to  prescribe  
cannabis  to  patients?  (i.e.  Do  you  believe  that  cannabis  should  be  legalized  for  
therapeutic  purposes?)  
 
Qualified  survey  questions  included  the  following  phrases:    
•   “Doctors  should  be  able  to  legally  prescribe  marijuana  as  medical  therapy”  
(Charuvastra,  Friedmann,  &  Stein,  2008  and  Philpot,  Ebbert,  &  Hurt,  2019).  
•   "Doctors  should  recommend  medical  marijuana  (MMJ;  as  medical  therapy)?"  
(Chan  et  al.,  2017  and  Kondrad  &  Reid,  2013).  
•   "Marijuana  should  be  made  available  by  prescription”  (Doblin  &  Kleiman,  1991;  
Schwartz,  Voth,  &  Sheridan,  1997;  Uritsky,  McPherson,  &  Pradel,  2011;  and  
Karanges,  Suraev,  Elias,  Manocha,  &  McGregor,  2018).  
•   "Cannabis  should  be  legalized/available  for  medicinal  purposes”  (Norberg  et  al.,  
2012;  Mathern,  Beninsig,  &  Nehlig,  2014;  Sideris  et  al.,  2018;  Bega,  Simuni,  
Okun,  Chen  &  Schmidt,  2016;  and  Crowley,  Collins,  Delargy,  Laird  &  Van  Hout,  
2017).  
•   "Clinicians  should  be  able  to  authorize  MC  without  fear  of  legal  action"  (Carlini,  
Garrett  &  Carter,  2015).  
•   "MMJ  should  be  legalized  in  all  states"  (Moeller  &  Woods,  2015).  
•   "Specialist  physicians  should  have  authority  to  prescribe  CTP”  (Ziemianski  et  al.,  
2015  and  Balneaves,  Alraja,  Ziemianski,  McCuaig  &  Ware,  2018).  
•   "The  use  of  CTP  should  be  legalized/approved  in  Serbia”  (Kusturica,  Tomas,  Sabo,  
Tomic  &  Horvat,  2019  and  Stojanovic  et  al.,  2017).  
•   "MD's  should  play  a  role  in  MMJ  authorization”  (Ebert  et  al.,  2015).  
•   "MJ  should  be  legalized  provided  it  is  under  medical  supervision”  (Burke  &  Marx,  
1971).  
•   “There  should  be  some  form  of  legalized  marijuana  use"  (Lieff  et  al.,  1973).  
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•   “Are  you  willing  to  help  patients  access  MMJ?”  (Ananth  et  al.,  2018).    
 
•   Research  question  2:  Do  you  feel  confident  in  your  level  of  knowledge  regarding  the  
health  effects  of  cannabis?    
  
Qualified  survey  questions  included  the  following  phrases:  
•   “Do  you  feel  confident  in  your  ability  to  prescribe  marijuana,  or  would  you  
require  more  knowledge  before  prescribing?”  (Doblin  &  Kleiman,  1991).  
•   “Self-­‐reported  knowledge  of  cannabis”  (reported  on  a  1-­‐5  Likert  scale;  responses  
of  3,  4,  or  5  [acceptable,  strong,  and  very  strong  knowledge,  respectively]  were  
approved  and  consolidated  for  analyses  reporting    “confidence  in  knowledge  of  
medicinal  cannabis”)  (Norberg  et  al.,  2012).  
•   “Self-­‐reported  knowledge  of  MMJ  efficacy”  (1-­‐5  Likert  scale;  responses  of  4  or  5  
[strong  and  very  strong  knowledge,  respectively]  were  approved  and  
consolidated  for  analyses  reporting  “confidence  in  knowledge  of  medicinal  
cannabis”)  (Ricco,  Danner,  Pereira  &  Philbrick,  2017).  
•   “How  much  knowledge  do  you  have  about  medical  marijuana?”  (6  categories:  
very  little  knowledge,  some  knowledge,  moderate  knowledge,  substantial  
knowledge,  high  level  of  knowledge,  and  professional  level  of  knowledge;  
“substantial  knowledge,”  “high  level  of  knowledge,”  and  “professional  level  of  
knowledge”  were  approved  and  consolidated  for  analyses  reporting  “confidence  
in  knowledge  of  medicinal  cannabis”)  (Szyliowicz  &  Hilsenrath,  2019).  
•   “Do  you  feel  adequately  prepared  to  answer  patients’  questions  about  MMJ?”  
(Philpot  et  al.,  2019).  
•   “Do  you  consider  yourself  well-­‐informed  about  the  endocannabinoid  system?”  
(Sideris  et  al.,  2018).  
•   “Do  you  consider  yourself  knowledgeable  about  MMJ  therapy?”  (Michalec,  Rapp  
&  Whittle,  2015  and  Mitchell,  Gould,  LeBlanc  &  Manuel,  2016).  
•   “Confidence  in  discussing  risks  and  benefits  of  medical  cannabis”  (4  categories:  
very  confident;  somewhat  confident;  somewhat  not  confident,  not  at  all  
confident;  “very  confident”  and  “somewhat  confident”  responses  were  
approved  and  consolidated  for  analyses  reporting  “confidence  in  knowledge  of  
medicinal  cannabis”)  (Zylla,  Steele,  Eklund,  Mettner  &  Arneson,  2018).  
•   “I  have  good  knowledge  around  the  (side)  effects  of  medicinal  cannabis"  
(Karanges  et  al.,  2018  and  Kusturica  et  al.,  2019).  
•   "I  know  how  to  talk  to  providers  about  the  risks  and  benefits  of  MMJ  use"  
(“confident”  and  “somewhat  confident”  responses  were  approved  and  
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consolidated  for  analyses  reporting  “confidence  in  knowledge  of  medicinal  
cannabis”)  (Caligiuri,  Ulrich  &  Welter,  2018).  
•   “Do  you  feel  sufficiently  knowledgeable  to  make  recommendations  regarding  
MMJ?"  (Braun  et  al.,  2018).  
•   “Self-­‐reported  competency  in  MMJ  pharmacology”  (1-­‐7  Likert  scale;  responses  of  
5-­‐7  [good,  very  good,  and  excellent,  respectively]  were  approved  and  
consolidated  for  analyses  reporting  “confidence  in  knowledge  of  medicinal  
cannabis”)  (Hwang,  Arneson  &  St.  Peter,  2016).  
•   "Do  you  feel  confident  regarding  your  current  knowledge  of  [cannabinoids]?  
(responses  of  “confident”  and  “somewhat  confident”  were  approved  and  
consolidated  for  analyses  reporting  “confidence  in  knowledge  of  medicinal  
cannabis”)  (Fitzcharles  et  al.,  2014  and  Ablin,  Elkayam  &  Fitzcharles,  2016).  
•   “Knowledge  of  pharmacology  and  indications"  (responses  indicating  a  “medium-­‐
high”  or  “high”  level  of  knowledge  were  approved  and  consolidated  for  analyses  
reporting  “confidence  in  knowledge  of  medicinal  cannabis”)  (Ebert  et  al.,  2015)  
•   "How  would  you  rate  your  knowledge  on  the  systemic  effects  of  cannabis?”  
(Crosby,  2018).  
•   “Rate  your  knowledge  on  factual  information  regarding  marijuana"  (responses  
indicating  “moderate”  and  “high”  levels  of  knowledge  were  approved  and  
consolidated  for  analyses  reporting  “confidence  in  knowledge  of  medicinal  
cannabis”)  (Burke  &  Marx,  1971).    
 
•   Research  question  3:  Do  you  believe  that  cannabis  has  any  therapeutic  utility?  
  
Qualified  survey  questions  included  the  following  phrases:  
•   “If  marijuana  were  legally  available,  I  would  recommend  the  use  of  marijuana  to  
a  patient”  (filed  under  the  survey  subscale  “belief  that  marijuana  has  medical  
benefits”)  (Chan  et  al.,  2017).  
•   “Marijuana  helps  patients  who  suffer  from  chronic,  debilitating  medical  
conditions”  (Ebert  et  al.,  2015;  Carlini  et  al.,  2015;  and  Kondrad  &  Reid,  2013).  
•   “Do  you  believe  that  MMJ  can  help  prevent  nausea  and  vomiting  (in  patients  
receiving  chemotherapy  or  radiation)?”  (Luba,  Earleywine,  Farmer  &  Slavin,  
2018;  Braun  et  al.,  2018;  and  Doblin  &  Kleiman,  1991).  
•   “Do  you  approve  of  using  MMJ  to  help  manage  patients’  symptoms?”  (Ananth  et  
al.,  2018).  
•   “Do  you  think  MMJ  has  medical  benefits/efficacy?”  (Uritsky  et  al.,  2011;  Mitchell  
et  al.,  2016;  and  Szyliowicz  &  Hilsenrath,  2019).  
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•   “Do  you  believe  legalization  [of  cannabis]  would  be  medically  efficacious?”  
(Cogswell  &  Harris,  2015).  
•   “Do  you  believe  that  MC  is  a  legitimate  medical  therapy?”  (Philpot  et  al.,  2019).  
•   “Do  you  recognize  MMJ  as  an  oncological  therapy?”  (Moeller  &  Woods,  2015).  
•   “Do  you  have  a  patient  who  you  agree  would  benefit  from  medical  cannabis?”  
(Karanges  et  al.,  2018).  
•   “To  what  extent  do  you  think  medical  marijuana  is  a  useful  adjunct  to  standard  
treatments  for  pain?”  (Braun  et  al.,  2018).  
•   “Are  you  certain  about  MMJ’s  therapeutic  value?”  (Ziemianski  et  al.,  2015  and  
Balneaves  et  al.,  2018).  
•   “Cannabis  has  a  role  in  palliative  care”  (Crowley  et  al.,  2017).  
•   “Assess  your  concern  regarding  the  limited  evidence  of  therapeutic  benefits  
from  MMJ”  (1-­‐7  Likert  scale  [1  =  least  concern,  7  =  most  concern];  responses  of  
1-­‐3  were  approved  and  consolidated  for  analyses  reporting  “confidence  in  
cannabis’  medical  efficacy”)  (Hwang  et  al.,  2016).  
•   “Do  you  believe  [medical]  marijuana/CBD  has  efficacy  in  treating  (childhood)  
epilepsy?”  (Jacobs,  Montebello,  Monds  &  Lintzeris,  2018;  Ablin  et  al.,  2016;  and  
Mathern  et  al.,  2015).  
•   “Do  you  believe  that  marijuana  has  an  acceptable  role  in  medicine?”  (Martins-­‐
Welch,  Nouryan,  Kline  &  Modayil,  2017).  
•   “I  am  familiar  with  the  possible  therapeutic  effects  of  cannabis”  (Kusturica  et  al.,  
2019).  
•   “Do  you  agree  that  cannabis  and  its  derivatives  could  potentially  have  
therapeutic  effects?”  (Stojanovic  et  al.,  2017).    
 
•   Research  question  4:  Do  you  believe  that  marijuana  should  be  legalized  for  recreational  
use?  
 
Qualified  survey  questions  included  the  following  phrases:    
•   “(Do  you  believe  that)  marijuana  should  be  legalized  for  recreational  use?”  
(Berlekamp,  Rao,  Patton  &  Berner,  2019;  Schwartz  et  al.,  1997;  Moeller  &  
Woods,  2015;  Chan  et  al.,  2017;  and  Kondrad  &  Reid,  2013).  
•   “What  legal  action  should  be  taken  for  the  possession  of  marijuana:  1)  No  legal  
action;  2)  Citation  with  a  fixed  fine;  3)  Misdemeanor;  4)  Felony?  (Linn,  Yager  &  
Leake,  1989).  
•   “Marijuana  should  be  regulated  in  the  same  way  as  alcohol”  (Lieff  et  al.,  1973).  
•   “Should  cannabis  be  made  recreational?”  (Bega  et  al.,  2017).  
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•   “Are  you  in  favor  of  legalizing  cannabis  for  non-­‐medical  purposes?”  (Ebert  et  al.,  
2015).  
•   “Free  access  should  be  granted  for  the  use  of  marijuana”  (Burke  &  Marx,  1971).  
•   “All  marijuana  should  be  legalized”  (Uritsky  et  al.,  2011).    
  
•   Research  question  5:  Do  you  desire  additional  education  regarding  MMJ  and/or  do  
believe  that  education  on  (medical)  cannabis  should  be  made  readily  available  to  
medical  professionals?    
  
Qualified  survey  questions  included  the  following  phrases:    
•   “(More)  training  about  medical  marijuana  should  be  incorporated  into  
medical/pharmacy  school  curriculum”  (Caligiuri  et  al.,  2018;  Moeller  &  Woods,  
2015;  Bega  et  al.,  2017;  and  Chan  et  al.,  2017).  
•   “Continuing  medical  education  (CME)  about  medical  marijuana  should  be  made  
available  to  (primary  care)  physicians”  (Carlini  et  al.,  2017;  Ebert  et  al.,  2015;  and  
Kondrad  &  Reid,  2013).  
•   “People  in  my  position  should  receive  education  about  cannabis”  (1-­‐5  Likert;  
responses  of  “somewhat  agree”  and  “fully  agree”  were  approved  and  
consolidated  for  analyses  reporting  “yes”  for  the  stated  research  question)  
(Norberg  et  al.,  2012).  
•   “Do  you  feel  that  more  education  about  marijuana  is  needed?”  (Szyliowicz  &  
Hilsenrath,  2019).  
•   “Are  you  interested  in  learning  more  about  MC?”  (Zylla  et  al.,  2018  and  Philpot  
et  al.,  2019).  
•   “It  would  be  helpful  to  have  additional  education  about  MMJ”  (Michalec  et  al.,  
2015).  
•   “How  strong  is  the  need  for  education  on  CTP?”  (responses  reporting  a  “strong”  
or  “very  strong”  need  were  approved  and  consolidated  for  analyses  reporting  
“yes”  for  the  stated  research  question)  (Ziemianski  et  al.,  2015  and  Balneaves  et  
al.,  2018).  
•     “Dispensing  cannabis  in  the  pharmacy  requires  additional  education”  
(Stojanovic  et  al.,  2017).    
  
6.   Research  question  6:  [For  U.S.-­‐based  papers  only]  Do  you  believe  that  the  United  States  
should  amend  cannabis’  federal  status  as  a  schedule  1  controlled  substance  (the  most  
restrictive  classification,  asserting  that  the  substance  has  no  accepted  medical  use)?    
 
Qualified  survey  questions  included  the  following  phrases:  
•   “Do  you  favor  the  Drug  Enforcement  Agency  (DEA)  reclassifying  marijuana  so  
that  it  is  no  longer  a  schedule  1  drug?”  (Bega  et  al.,  2017;  Chan  et  al.,  2017;  and  
Kondrad  &  Reid,  2013).  
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•   “Do  you  support  the  rescheduling  of  marijuana  to  permit  its  use  in  medicine?”  
(Schwartz  et  al.,  1997  and  Doblin  &  Kleiman,  1991).  
•   “Cannabis  should  be  rescheduled  so  that  it  is  no  longer  a  schedule  1  drug  with  no  
medical  benefits”  (Carlini  et  al.,  2017).  
•   “Do  you  favor  change  in  (federal)  marijuana  control?”  (Burke  &  Marx,  1971).    
 
7.     Research  question  7:  Are  you  concerned  about  cannabis’  dependence/addiction  
potential?      
  
Qualified  survey  questions  included  the  following  phrases:  
•   “(Do  you  believe  that)  marijuana  can  be  addictive  (yes/no)?”  (Kusturica  et  al.,  
2019;  Uritsky  et  al.,  2011;  Carlini  et  al.,  2017;  Chan  et  al.,  2017;  and  Kondrad  &  
Reid,  2013).  
•   “Are  you  concerned  about  substance  abuse  among  patients  who  receive  MMJ?”  
(Ananth  et  al.,  2018).  
•   “Are  you  concerned  with  MMJ’s  potential  for  abuse/misuse/diversion?”  
(Michalec  et  al.,  2015).  
•   “Do  you  believe  /  are  you  concerned  that  addiction  and  dependence  are  
potential  side  effects  of  MC?”  (Stojanovic  et  al.,  2017;  Martins-­‐Welch  et  al.,  
2017;  and  Karanges  et  al.,  2018).  
•   “On  the  scale  of  1-­‐7  (1  =  no  concern,  7  =  most  concern),  how  concerned  are  you  
about  the  psychoactive  effect  and  potential  addiction  from  cannabis  use?”  
(responses  of  5-­‐7  were  approved  and  consolidated  for  analyses  reporting  
“concern  about  MMJ’s  addictive  potential”)  (Hwang  et  al.,  2016).  
•   “The  risk  of  addiction/physiological  dependence  would  reduce  my  willingness  to  
prescribe  MMJ  (1-­‐5  Likert  scale  [1  =  would  not  reduce  my  prescribing,  5  =  would  
greatly  reduce  my  prescribing];  responses  of  4  and  5  were  approved  and  
consolidated  for  analyses  reporting  “concern  about  MMJ’s  addictive  potential”)  
(Jacobs  et  al.,  2018).      
 
Statistical  Analysis:    
 
IBM  SPSS  version  25  (IBM  Corp.,  Armonk,  NY:  IBM  Corp.)  was  used  to  run  all  statistical  
analyses.  Tests  performed  included  Pearson’s  r  bivariate  correlations  and  2x2  Chi-­‐square  
(χ2)  tests.  Pearson’s  r  was  used  to  determine  the  significance  of  correlations  between  two  
continuous  variables  (e.g.  percentages  and  years  of  publication)  and  chi-­‐square  tests  were  
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used  to  assess  relationships  between  two  categorical  variables  (e.g.  proportion  of  
respondents  reporting  yes  vs.  no  and  respondent  subgroups  [i.e.  students  vs.  medical  
professionals]);  for  both  tests,  p-­‐values  below  .05  constituted  statistical  significance.    
   In  this  systematic  review,  chi-­‐square  tests  were  used  to  assess  the  presence  or  
absence  of  statistically-­‐significant  differences  between  the  two  main  survey  cohorts—  
medical  students  and  medical  professionals—with  respect  to  their  knowledge  and  opinions  
concerning:  MC  legalization  (research  question  1,  Fig.  4);  self-­‐reported  confidence  regarding  
one’s  knowledge  of  MC  (research  question  2,  Fig.  7);  belief  in  MC’s  medical  utility  (research  
question  3,  Fig.  9);  support  for  recreational  legalization  of  cannabis  (research  question  4,  
Fig.  12);  and  support  for  the  U.S.  government’s  federal  rescheduling  of  cannabis  (research  
question  6,  Fig.  14).  For  these  analyses,  the  total  number  of  individual  respondents  from  all  
the  relevant  studies  who  reported  either  “yes”  or  “no”  to  each  research  question  were  
pooled  into  groups  (i.e.  all  medical  professional  respondents  reporting  yes;  all  student  
respondents  reporting  no,  etc.),  then,  a  chi-­‐square  analysis  determined  if  there  were  
significant  differences  in  the  relative  frequencies  between  each  category.    
   Additionally,  Pearson’s  r  bivariate  correlations  were  used  to  assess  any  relevant  
differences  in  entire  studies’  responses  to  the  research  questions  over  time  (i.e.  by  the  year  
of  the  study’s  publication).  In  this  systematic  review,  Pearson’s  r  was  used  to  assess  
significant  temporal  trends  regarding  respondents’:  support  for  the  legalization  of  MC  (both  
medical  professionals  and  students  together,  and  just  medical  professionals  alone;  research  
question  1,  Figs.  1  &  2);  support  for  the  recreational  legalization  of  cannabis  (research  
question  4,  Fig.  11);  desire  for  more  educational  material  regarding  MC  (research  question  
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5,  Fig.  13);  and  concern  about  MC’s  potential  to  cause  addiction  and  dependence  (research  
question  7,  Fig.  15).    
Furthermore,  some  temporal  analyses  (all  using  Pearson’s  r  bivariate  correlations)  
assessed  respondents’  opinions  regarding  MC  with  respect  to  the  number  of  years  
preceding  or  following  MC  legalization  in  the  state  or  country  of  the  study’s  publication.  For  
these  analyses,  the  year  of  MC  legalization  was  identified  for  each  state  or  country  and  
labeled  as  “year  0”;  then,  the  year  of  MC  legalization  was  subtracted  from  the  year  of  the  
study’s  publication  to  yield  the  number  of  years  distancing  the  study  from  the  year  of  MC  
legalization.  For  example,  Australia  legalized  MC  in  2016,  and  Norberg,  et  al.  (Australia)  
published  their  study  in  2012;  therefore,  Norberg,  et  al.  (2012)  received  a  score  of  -­‐4  (years)  
with  respect  to  years  preceding  or  following  MC  legalization  (2012-­‐2016  =  -­‐4).  This  type  of  
analysis  was  used  to  assess  temporal  trends  regarding  respondents’:  support  for  the  
legalization  of  MC  (research  question  1,  Fig.  3)  and  self-­‐reported  confidence  regarding  one’s  
knowledge  of  MC  (research  question  2,  Fig.  6).    
Finally,  some  temporal  analyses  featured  a  preponderance  of  studies  conducted  in  a  
truncated  time  period,  with  only  a  few  outlying  studies  published  many  years  apart  from  
the  central  cohort;  in  these  instances,  the  outliers  were  excluded  from  analysis.  For  
example,  figure  1  assessed  respondents’  attitudes  towards  MC  legalization  over  time,  and  
featured  15  (out  of  21)  studies  published  in  2015  or  later.  Therefore,  the  two  studies  
conducted  in  the  1970’s  were  excluded  from  this  analysis  due  to  their  extreme  deviation  





An  analysis  of  question  1  (Do  you  believe  that  physicians  deserve  the  legal  right  to  
prescribe  cannabis  to  patients?  [i.e.  Do  you  believe  that  cannabis  should  be  legalized  for  
therapeutic  purposes?])  found  that  both  medical  students’  and  professionals’  support  for  
the  legalization  of  MC  has  significantly  increased  over  time  (r(19)  =  .44,  p  =  .045;  1990  to  
present;  Fig.  1).    
  
Figure  1.  The  percentage  of   respondents’  agreeing  with  question  1   (Do  you  believe  that  
physicians  deserve  the  legal  right  to  prescribe  cannabis  to  patients?  [i.e.  Do  you  believe  that  
cannabis  should  be   legalized   for   therapeutic  purposes?])  with  respect   to   the  year  of   the  
study’s  publication  (2  pre-­‐1990  outliers  removed;  21  studies  total;  r(19)  =  .44,  p  =  .045).  
  
Additionally,  an  analysis  of  only  medical  professionals  (i.e.  following  the  removal  of  the  4  
student-­‐only  studies)  yielded  a  similar  trend  regarding  increased  support  for  the  legalization  
of  MC  with  respect  to  time,  but  the  correlation  did  not  meet  statistical  significance  (r(15)  =  















Figure  2.  The  percentage  of  professional  respondents’  agreeing  with  question  1  (Do  you  
believe  that  physicians  deserve  the  legal  right  to  prescribe  cannabis  to  patients?  [i.e.  Do  
you  believe  that  cannabis  should  be  legalized  for  therapeutic  purposes?]),  with  respect  
to  the  year  of  the  study’s  publication  (post-­‐1990  studies  only;  17  studies  total;  r(15)  =  
.42,  p  =  .093).  
  
  In  assessing  whether  the  amount  of  years  following  or  preceding  the  legalization  of  MC  in  
the  state  or  country  of  a  study’s  publication  affected  respondents’  support  for  the  
legalization  of  MC,  no  significant  correlation  was  observed  (r(9)  =  .25,  p  =  .453;  Fig.  3).    
  
Figure  3.  The  percentage  of   respondents’   (both  professionals   and   students)   agreeing  
with   question   1   (Do   you   believe   that   physicians   deserve   the   legal   right   to   prescribe  
cannabis   to   patients?   [i.e.   Do   you   believe   that   cannabis   should   be   legalized   for  
therapeutic   purposes?])   compared   to   the   amount   of   years   separating   the   year   of  
publication   from   the   year   MC   was   legalized   in   the   state   of   country   of   the   study’s  
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Comparing  students’  attitudes  towards  the  legalization  of  MC  against  those  of  medical  
professionals  revealed  a  significant  difference  between  the  two  cohorts,  with  medical  
professionals  favoring  legalization  at  a  significantly  higher  rate  than  students  (52%  vs.  42%,  
respectively;  χ2  (1,  N  =  9019)  =  50.72  p  <  .001;  Fig.  4).    
  
Figure  4.  The  percentage  of  respondents  agreeing  with  research  question  1  (Do  you  believe  
that   physicians   deserve   the   legal   right   to   prescribe   cannabis   to   patients?   [i.e.   Do   you  
believe   that   cannabis   should   be   legalized   for   therapeutic   purposes?])   –   based   on  
respondent   status   as   either   a   healthcare   professional   (N   =   7108)   or   as   a   medical   or  
pharmacy  student  (N  =  1911)  (χ2  (1,  N  =  9019)  =  50.72,  p  <  .001). 
 
Finally,  figure  5  shows  that  support  for  the  legalization  of  MC  varies  by  the  country  of  the  
study’s  publication;  Canada  demonstrated  the  greatest  support  for  the  legalization  of  MC  
(89%,  N  =  608,  2  studies)  and  the  United  States  demonstrated  the  least  support  for  the  























Respondent  type  /  Professional  status
 25 
  
Figure  5.  The  percentage  of  respondents  agreeing  with  research  question  1  (Do  you  believe  
that  physicians  deserve  the  legal  right  to  prescribe  cannabis  to  patients?  [i.e.  Do  you  believe  
that   cannabis  should  be   legalized   for   therapeutic  purposes?])  –  based  on   country  of   the  
study’s  publication  (USA  [N  =  5853];  Australia  [N  =  1304];  Ireland  [N  =  565];  Canada  [N  =  
608];  Serbia  [N  =  396];  and  Israel  [N  =  71]).    
  
Research  question  2  evaluated  respondents’  self-­‐reported  level  of  confidence  
regarding  their  knowledge  of  cannabis  and  its  health  effects.  In  assessing  whether  the  
amount  of  years  following  or  preceding  the  legalization  of  MC  in  the  state  or  country  of  a  
study’s  publication  affected  respondents’  self-­‐reported  level  of  confidence,  no  statistically-­‐
significant  relationship  was  observed  (r(13)  =  .32,  p  =  .246;  Fig.  6).  
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Figure  6.  Survey  respondents’  self-­‐reported   level  of  knowledge  about  MC  (%  claiming  an  
adequate  level  of  knowledge,  or  better)  compared  to  the  amount  of  years  separating  the  
year  of  publication  from  the  year  MC  was  legalized  in  the  state  of  country  of  the  study’s  
publication  (15  studies;  r(13)  =  .32,  p  =  .246)  
  
  Analysis  of  respondents’  self-­‐reported  confidence  (regarding  knowledge  of  MC)  by  
respondent  type  (medical  professionals  vs.  students)  reveals  significant  differences  between  
the  two  cohorts  (χ2  (1,  N  =  6711)  =  293.88,  p  <  .001;  Fig.  7);  overall,  students  reported  the  
greatest  confidence  in  their  self-­‐reported  knowledge  of  MC,  with  medical  professionals  (on  
average)  reporting  significantly  lower  rates  of  confidence  regarding  their  knowledge  of  MC  
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Figure  7.  Respondents’  self-­‐reported  confidence  in  their  knowledge  of  MC  (%  claiming  an  
adequate   level   of   knowledge,  or  better)   by   respondent   type:  medical   professionals   (N   =  
5035)  vs.  students  (N  =  1676)  (χ2  (1,  N  =  6711)  =  293.88,  p  <  .001).    
  
Finally,  figure  8  shows  that  respondents’  self-­‐reported  confidence  in  their  knowledge  of  MC  
varies  by  the  country  of  the  study’s  publication;  Israeli  respondents  reported  the  highest  
rates  of  self-­‐reported  confidence  in  their  knowledge  of  MC  (67%,  N  =  94;  2  studies),  while  
Canadian  respondents  reported  the  lowest  rates  of  self-­‐reported  confidence  in  their  
knowledge  of  MC  (18%,  N  =  876;  2  studies).    
  
  
Figure  8.  Respondents’  self-­‐reported  confidence  in  knowledge  regarding  MC  (%  claiming  
an   adequate   level   of   knowledge,   or   better)   by   country   of   the   study’s   publication:  




Research  question  3  assessed  respondents’  belief  in  cannabis’  medical  utility.  A  
comparison  of  medical  students’  versus  medical  professionals’  belief  in  cannabis’  medical  
utility  yielded  a  significant  difference,  with  students  reporting  greater  faith  in  cannabis’  
medical  utility  than  medical  professionals  (77%  vs  65%,  respectively;  χ2  (1,  N  =  8647)=  59.64,  
p  <  .001;  Fig.  9).    
  
Figure  9.  Percentage  of  respondents’  espousing  belief  in  cannabis’  medical  
efficacy  by  respondent  type:  medical  professionals  (N  =  7529)  and  students  (N  
=  1118)  (χ2  (1,  N  =  8647)  =  59.64,  p  <  .001).  
  
Additionally,  figure  10  shows  that  respondents’  belief  in  cannabis’  medical  utility  varies  by  
the  country  of  the  study’s  publication;  Serbian  respondents  reported  the  highest  rates  of  
belief  in  cannabis’  medical  utility  (84%,  N  =  396;  2  studies)  while  Australian  respondents  




Figure  10.  Percentage  of  respondents’  espousing  belief   in  cannabis’  medical  utility  by  
country  of   the  study’s  publication:  USA  (N  =  5260);  Canada  (N  =  1353);  Australia  (N  =  
726);  Ireland  (N  =  565);  Israel  (N  =  95);  and  Serbia  (N  =  396).  
  
Research  question  4  evaluated  respondents’  belief  that  cannabis  should  be  legalized  
for  recreational  (i.e.  non-­‐medical)  purposes.  In  assessing  whether  medical  students’  and  
professionals’  attitudes  towards  the  legalization  of  recreational  cannabis  has  changed  over  
time,  no  statistically-­‐significant  relationship  was  observed  (r(9)  =  .11,  p  =  .746;  Fig.  11).  
  
Figure  11.  Percentage  of  survey  respondents’  espousing  support  for  the  legalization  
of   cannabis   for   recreational   (non-­‐medical)   purposes   by   year   of   publication   (11  

































  A  comparison  of  medical  students’  versus  medical  professionals’  attitudes  regarding  the  
recreational  legalization  of  cannabis  yielded  a  statistically-­‐significant  difference,  with  
students  demonstrating  greater  support  for  recreational  legalization  than  medical  
professionals  (43%  vs.  30%,  respectively;  χ2  (1,  N  =  4136)  =  78.88,  p  <  .001;  Fig.  12).    
  
Figure   12.   Percentage   of   respondents’   espousing   support   for   legalization   of  
recreational  cannabis  use  by  respondent  type:  students  (N  =  1834)  vs.  medical  
professionals  (i.e.  MD’s,  Pharm.D.’s,  DO’s,  PA’s,  RN’s;  N  =  2302)    (χ2  (1,  N  =  4136)  
=  78.88,  p  <  .001).  
  
Research  question  5  assessed  whether  respondents  desired  more  education  about  
MC,  and  if  they  believed  that  information  about  MC  should  be  incorporated  into  medical  
school  curricula.  An  assessment  of  respondents’  personal  or  general  desire  for  more  
knowledge  regarding  MC  with  respect  to  the  year  of  the  study’s  publication  yielded  no  


































Figure   13.  Percentage   of   survey   respondents   reporting   a   personal   or   general  
desire  for  more  education  on  MC  by  year  of  publication  (15  studies,  r(13)  =  -­‐.10,  
p  =  .713).    
  
Research  question  6  assessed  U.S.-­‐based  respondents’  opinions  regarding  the  
federal  rescheduling  of  cannabis.  A  comparison  of  medical  students  versus  professionals  
yielded  significant  differences  regarding  each  group’s  level  of  support  for  the  federal  
rescheduling  of  cannabis,  with  students  supporting  more  lenient  federal  regulations  at  a  
higher  rate  than  professionals  (60%  vs.  46%,  respectively;  χ2  (1,  N    =  4249)  =  70.76,  p  <  .001;  


























Figure   14.   Percentage   of   respondents   (U.S.   only)   espousing   support   for   the  
federal   rescheduling   of   cannabis   by   respondent   type/professional   status:  
medical   professionals   (i.e.  MD’s,   Pharm.D.’s,   DO’s,   PA’s,   RN’s;  N   =   3045)   vs.  
students  (N  =  1204)  (χ2  (1,  N  =  4249)=  70.76,  p  <  .001).  
  
Finally,  research  question  7  asked  respondents  if  they  were  concerned  about  MC’s  
potential  to  cause  addiction  or  dependence  in  patients.  In  assessing  whether  respondents’  
levels  of  concern  regarding  MC’s  potential  to  cause  addiction  or  dependence  has  changed  
over  time,  no  statistically-­‐significant  relationship  was  observed  (r(11)  =  -­‐.13,  p  =  .673;  Fig.  
15).    
  
Figure   15.   The   percentage   of   survey   respondents   who   are   concerned   about  
MMJ’s  addiction/dependence  potential  by  year  of  publication  (13  studies;  r(11)  

































































This  systematic  review  assessed  contemporary  and  relevant  trends  pertaining  to  
medical  professionals’  and  students’  opinions  and  knowledge  regarding  medicinal  cannabis  
(MC).  The  analyses  conducted  in  this  review  sought  to  address  the  following  five  specific,  
guiding  research  questions:    
1.   Do  healthcare  students  and  professionals  believe  that  cannabis  should  be  legalized  
for  medicinal  purposes?  Have  these  opinions  changed  significantly  over  time?  
  
2.   Are  healthcare  students  and  professionals  confident  in  their  level  of  knowledge  
regarding  cannabis’  health  effects  and  clinical  applications?  
  
3.   Are  healthcare  students  and  professionals  adequately  convinced  of  cannabis’  
therapeutic  utility?  What  are  healthcare  professionals’  main  concerns  regarding  the  
incorporation  of  cannabis  into  the  medical  system?    
  
4.   What  current  gaps  in  knowledge  exist,  and  how  can  the  medical  community  become  
better  informed  about  the  therapeutic  uses  of  cannabis?  
 
5.   Are  there  significant  differences  between  the  knowledge  and  opinions  of  healthcare  
students’  versus  healthcare  professionals’  with  respect  to  any  of  the  
aforementioned  research  questions?  
  
  
With  respect  to  research  question  1,  it  was  hypothesized  that  support  for  the  legalization  of  
MC  would  increase  over  time.  For  research  question  5  (whose  significance  applies  to  all  
other  questions),  it  was  expected  that  students  would  demonstrate  greater  support  for  the  
legalization  of  MC  than  medical  professionals.  Regarding  research  question  2,  it  was  
hypothesized  that  confidence  levels  would  rise  as  the  number  of  years  following  MC  
legalization  in  the  country  of  a  study’s  publication  increased;  moreover,  it  was  expected  
that  professionals  (as  opposed  to  students)  would  express  greater  confidence  in  their  
knowledge  of  MC.  For  question  3,  it  was  hypothesized  that  respondents’  from  more  
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recently  published  studies  would  espouse  greater  faith  in  cannabis’  medical  utility;  
additionally,  it  was  predicted  that  students  would  express  greater  faith  in  cannabis’  medical  
utility.  Finally,  with  respect  to  research  question  4,  it  was  expected  that  respondents  from  
more  recent  studies  would  express  an  increased  desire  for  further  education.    
Altogether,  this  systematic  review  identified  several  significant  trends  pertaining  to  
medical  students’  and  professionals’  knowledge  and  attitudes  regarding  MC.  Most  notably,  
it  was  found  that  both  medical  students’  and  professionals’  support  for  the  legalization  of  
MC  has  significantly  increased  over  the  last  three  decades,  and  that  medical  professionals  
are  more  likely  to  endorse  the  legalization  of  MC  than  students  (52%  vs.  42%,  respectively).  
Furthermore,  an  assessment  of  both  respondents’  desire  for  more  educational  material  on  
MC  and  respondents’  concerns  regarding  MC’s  potential  to  cause  dependence  and  
addiction  showed  a  ceiling  effect,  with  respondents  consistently  reporting  high  levels  of  
desire  for  more  educational  material  and  a  high  level  of  concern  regarding  MC’s  addictive  
potential,  but  with  no  significant  changes  over  time.  Lastly,  support  for  the  legalization  of  
MC,  respondents’  self-­‐reported  confidence  regarding  their  knowledge  of  MC,  and  
respondents’  belief  in  cannabis’  medical  utility  all  showed  considerable  differences  across  
countries.  
   Question  1  assessed  respondents’  support  for  the  legalization  of  MC.  It  was  
expected  that  support  for  the  legalization  of  MC  would  increase  over  time  due  to  ongoing  
sociocultural  and  legislative  trends  favoring  legalization,  which  may  serve  to  reduce  stigma  
and  increase  the  normalization  of  cannabis  within  the  medical  community.  Results  from  this  
systematic  review  supported  the  hypothesis,  as  respondents’  level  of  support  for  the  
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legalization  of  MC  was  shown  to  significantly  increase  from  1990  to  the  present  day  (see  Fig.  
1).  Also,  it  was  expected  that  students  would  demonstrate  greater  support  for  the  
legalization  of  MC  than  medical  professionals,  given  the  premise  that  many  medical  
professionals  may  have  been  educated  during  an  era  in  which  cannabis  was  largely  
demonized  within  society  and  the  medical  community,  and  the  established  research  finding  
that  (at  least  within  the  United  States)  younger  individuals  are  adopting  more  permissive  
views  towards  marijuana  (Schmidt  et  al.,  2016).  However,  results  from  this  systematic  
review  actually  indicated  the  reverse,  with  medical  professions  demonstrating  greater  
support  for  the  legalization  of  MC  than  students  (see  Fig.  2).  This  finding  can  perhaps  be  
explained  by  entertaining  the  premise  that  students  may  want  to  espouse  more  orthodox  
viewpoints  during  their  educational  years,  so  as  not  to  appear  overly  progressive  and  
radical,  which  could  possibly  jeopardize  their  clinical  accreditation.  Furthermore,  it  was  
hypothesized  that  respondents’  support  for  the  legalization  of  MC  would  be  highest  in  
countries  that  took  early  legislative  steps  to  legalize  MC,  due  to  the  established  research  
finding  that  the  passage  of  medical  marijuana  laws  tends  to  correlate  with  more  lenient  
views  towards  cannabis–  especially  among  younger  people  (Schmidt  et  al.,  2016);  this  
expectation  was  largely  confirmed,  as  Canadian  respondents  demonstrated  the  greatest  
support  for  the  legalization  of  MC  (89%),  while  U.S.  respondents  demonstrated  the  least  
support  for  the  legalization  of  MC  (42%).  Canada  legalized  MC  nationwide  in  2001,  while  
many  states  within  the  U.S.  still  fully  prohibit  the  medical  prescription  of  cannabis.    
Question  2  assessed  respondents’  self-­‐reported  confidence  regarding  their  
knowledge  of  MC.  It  was  hypothesized  that  confidence  levels  would  rise  as  the  number  of  
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years  following  MC  legalization  in  the  country  of  a  study’s  publication  increased,  due  to  
respondents’  from  those  countries  having  an  increased  likelihood  of  being  exposed  to  
cannabis  in  clinical  settings;  however,  no  statistically-­‐significant  relationship  was  observed  
(see  Fig.  4).  Moreover,  it  was  expected  that  professionals  (as  opposed  to  students)  would  
express  greater  confidence  in  their  knowledge  of  MC,  given  their  more  extensive  medical  
training  and  clinical  experience;  however,  the  opposite  result  was  observed  with  57%  of  
students  reporting  an  adequate  (or  better)  knowledge  of  MC  and  just  33%  of  medical  
professionals  reporting  an  adequate  (or  better)  knowledge  of  MC  (see  Fig.  5).  This  finding  
could  be  the  result  of  students—and  younger  respondents  in  general—having  more  lenient  
attitudes  towards  cannabis,  thereby  resulting  in  a  greater  perceived  sense  of  knowledge  
about  MC–  or,  it  could  be  a  manifestation  of  the  Dunning-­‐Kruger  effect,  a  cognitive  bias  in  
which  individuals  with  an  inferior  understanding  of  a  concept  tend  to  overestimate  their  
own  perceived  level  of  knowledge  (Kruger  &  Dunning,  1999).  Furthermore,  it  was  
hypothesized  that  respondents  from  countries  with  a  longstanding  legal  acceptance  of  MC  
would  demonstrate  greater  levels  of  confidence  regarding  their  knowledge  of  MC  under  the  
premise  that  respondents’  from  those  countries  would  have  an  increased  likelihood  of  
being  exposed  to  cannabis  in  clinical  settings.  The  data  largely  supported  this  hypothesis,  as  
Israeli  respondents  (where  MC  has  been  legal  since  1973)  reported  the  greatest  levels  of  
confidence  (67%,  see  Fig.  6),  while  Canadian  respondents  (where  MC  has  been  legal  since  
2001)  reported  the  lowest  levels  of  confidence  (18%).    
Question  3  investigated  respondents’  belief  in  cannabis’  medical  utility.  It  was  
hypothesized  that  students  would  express  greater  faith  in  cannabis’  medical  utility  under  
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the  premise  that  students  (being  younger,  on  average,  than  professionals)  would  be  more  
likely  to  have  been  raised  in  a  sociopolitical  climate  more  accepting  of  cannabis’  medical  
applications.  This  hypothesis  was  supported  by  the  data,  with  77%  of  students  expressing  
belief  in  cannabis’  medical  utility  as  opposed  to  65%  of  medical  professionals  (see  Fig.  7).  
Similarly,  it  was  anticipated  that  respondents’  from  countries  with  a  longstanding  legal  
acceptance  of  MC  would  espouse  greater  faith  in  cannabis’  medical  utility;  however,  the  
data  did  not  support  this  hypothesis,  as  Serbian  respondents  reported  the  greatest  belief  in  
cannabis’  medical  utility  (84%,  see  Fig.  8)  despite  the  fact  that  MC  remains  illegal  in  Serbia,  
while  Australian  respondents  reported  the  lowest  levels  of  belief  in  cannabis’  medical  utility  
(49%),  despite  the  fact  that  Australia  federally  legalized  MC  in  2016.  The  Serbian  
respondents’  exceptionally  high  faith  in  cannabis’  medical  utility,  despite  its  nationwide  
illegality,  once  again  suggests  a  Dunning-­‐Kruger  effect,  as  these  physicians  are  unlikely  to  
have  significant  clinical  experience  with  MC.    
Research  question  4  assessed  respondents’  support  for  the  recreational  legalization  
of  cannabis.  It  was  expected  that  support  for  recreational  legalization  would  increase  over  
time  due  to  ongoing  sociopolitical  trends  favoring  the  decriminalization  and  legalization  of  
recreational  cannabis;  however,  no  significant  trends  were  observed  over  time  (see  Fig.  9).  
Rather,  the  data  indicates  that  approximately  one  in  two  respondents  (i.e.  50%)  favor  the  
legalization  of  recreational  cannabis,  regardless  of  the  year  of  the  study’s  publication.  
Likewise,  it  was  expected  that  students  would  express  greater  support  for  recreational  
cannabis,  under  the  premise  that  younger  respondents  tend  to  hold  more  permissive  views  
toward  cannabis  regulation  (Schmidt  et  al.,  2016).  The  results  supported  this  hypothesis,  as  
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43%  of  students  reported  support  for  recreational  legalization,  as  opposed  to  only  30%  of  
medical  professionals  (see  Fig.  10).    
Question  5  assessed  respondents’  desire  for  more  educational  material  regarding  
MC,  including  supplemental  educational  programs  for  professionals,  and  the  incorporation  
of  cannabis-­‐related  material  into  the  existing  medical  school  curriculum.  It  was  expected  
that  respondents  from  more  recent  studies  would  express  an  increased  desire  for  further  
education,  given  the  heightened  acceptance  of  cannabis  as  a  legitimate  medical  therapy  in  
recent  years.  However,  no  significant  change  in  respondents’  desire  for  more  education  was  
observed  over  time,  and  the  data  actually  indicated  an  apparent  ceiling  effect,  with  around  
80%  of  respondents  desiring  more  educational  material–  regardless  of  the  year  of  the  
study’s  publication  (see  Fig.  11).    
Research  question  6  assessed  U.S.-­‐based  respondents’  opinions  regarding  the  
federal  rescheduling  of  cannabis.  Once  again,  it  was  expected  that  students  would  express  
greater  support  for  the  federal  rescheduling  of  cannabis,  under  the  principle  that  younger  
respondents  tend  to  espouse  more  permissive  views  towards  cannabis  regulation  (Schmidt  
et  al.,  2016).  The  data  supported  this  hypothesis,  as  60%  of  students  indicated  support  for  
more  lenient  federal  restrictions  of  cannabis  use,  as  opposed  to  only  46%  of  medical  
professionals  (see  Fig.  12).    
Lastly,  research  question  7  asked  respondents  if  they  were  concerned  about  MC’s  
potential  to  cause  addiction  or  dependence  in  patients.  It  was  expected  that  older  studies  
would  reflect  greater  levels  of  concern,  given  the  established  research  finding  that  the  
perceived  harmfulness  of  marijuana  has  decreased  significantly  since  1991  (Keyes  et  al.,  
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2016).  However,  no  significant  change  over  time  was  observed,  and  the  results  indicated  a  
potential  ceiling  effect,  with  approximately  one  in  two  respondents  (i.e.  50%)  expressing  
concern  for  MC’s  addiction  and  dependence  potential,  regardless  of  the  year  of  the  study’s  
publication  (see  Fig.  13).    
   It  is  important  to  note  that  this  systematic  review  was  impacted  by  several  
identifiable  limitations.  Firstly,  there  was  a  general  dearth  of  accessible  studies  reporting  
medical  professionals’  and  students’  knowledge  and  attitudes  regarding  MC;  however,  the  
43  studies  included  in  this  systematic  review  provided  sufficient  data  to  yield  substantive  
and  meaningful  results.  Notwithstanding,  there  was  significant  variability  between  the  
individual  studies,  including:  incongruency  in  the  survey  methods  and  individual  
phraseologies  used  in  data  collection;  differences  in  cannabis  regulatory  policy  in  the  states  
and  countries  in  which  the  surveys  were  conducted;  and  differences  in  the  proportions  of  
the  types  of  respondents  who  answered  the  surveys  (i.e.  MD’s,  pharmacists,  RN’s,  etc.).  For  
instance,  many  studies  included  cohorts  of  medical  professionals  who  specialized  in  a  
variety  of  subfields  (e.g.  neurology,  pharmacy,  oncology,  rheumatology,  etc.);  therefore,  the  
analyses  presented  in  this  systematic  review  are  generalized  findings  that  combine  the  
responses  of  all  medical  professional  subtypes.  This  necessary  methodological  procedure  
led  to  the  overall  generalization  of  the  medical  professional  cohort,  consequently  nullifying  
any  potential  differences  or  distinctions  within  the  overarching  “medical  professional”  
group.  In  addition,  far  more  studies  assessed  the  opinions  of  medical  professionals  (32  
studies)  as  opposed  to  those  of  medical  students  (9  studies),  which  limits  the  strength  of  
the  comparisons  made  between  the  two  cohorts.  Also,  while  the  43  studies  provided  
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enough  data  to  conduct  a  meaningful  systematic  review,  most  did  not  provide  the  
necessary  metrics  required  to  perform  an  even  more  comprehensive  meta-­‐analysis.  Going  
forward,  more  studies  should  begin  to  yield  the  requisite  effect  sizes  required  to  perform  
meta-­‐analyses  as  the  surveys  used  in  these  studies  begin  to  include  more  data  pertaining  to  
mediation  analyses  and  pre/post  comparisons.    
   Furthermore,  it  was  not  possible  to  accurately  assess  countrywide  (U.S.,  specifically)  
differences  in  respondents’  knowledge  and  attitudes  regarding  MC  due  to:  an  insufficient  
number  of  representative  studies  from  all  U.S.  states;  highly  variable  sample  sizes  between  
studies  conducted  in  different  states;  and  the  highly  disparate  legislative  policies  regarding  
(medicinal)  cannabis  in  U.S.  states.  In  addition,  a  major  preponderance  of  studies  collected  
for  this  systematic  review  were  published  after  2010  (37  out  of  43),  which  limits  the  
statistical  power  of  long-­‐term  temporal  analyses,  resulting  in  a  reduced  range  of  years  in  
which  comparisons  can  be  made  to  assess  changes  in  knowledge  and  attitudes  over  time.    
   Crucially,  this  systematic  review  has  important  implications  for  both  the  continued  
adoption  of  MC  within  the  global  medical  community  and  for  the  possible  implementation  
of  therapeutic  hallucinogens  into  generally  accepted  medical  practice.  Firstly,  the  results  
from  this  review  indicate  that  clinicians’  acceptance  of  MC—a  controversial,  formerly  
stigmatized  alternative  therapy—has  significantly  increased  in  recent  decades,  which  
suggests  that  a  similar  trend  may  arise  with  respect  to  hallucinogens,  given  their  analogous  
status  as  a  culturally  stigmatized  alternative  therapy.  Moreover,  results  from  this  review  
clearly  show  that  medical  professionals’  strong  desire  for  more  educational  material  on  MC  
has  not  significantly  changed  over  the  last  several  decades.  Hence,  it  would  strongly  
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behoove  the  medical  community  to  begin  acknowledging  this  widespread  and  longstanding  
desire  for  more  education,  as  it  can  only  serve  to  benefit  both  medical  professionals  and  
patients  to  have  a  clinical  staff  that  is  well-­‐versed  and  confident  regarding  their  knowledge  
of  alternative  therapies.  Providing  clinicians  with  comprehensive  and  scientifically-­‐sound  
educational  material  regarding  the  effects  of  alternative  therapies  will  be  a  major  step  in  
assuaging  the  ongoing  stigma  and  misinformation  currently  surrounding  both  MC  and  
hallucinogens  within  the  medical  community.  However,  it  must  not  be  overlooked  that  at  
the  present  moment,  very  little  educational  material  is  even  available  regarding  cannabis  
and  hallucinogens  due  to  the  preponderance  of  highly  restrictive  legislative  policies  which  
limits  their  status  as  subjects  of  scientific  inquiry.  Lastly,  results  from  this  review  found  that  
medical  students  are  significantly  more  likely  to  report  high  levels  of  confidence  regarding  
their  knowledge  of  MC  compared  to  medical  professionals,  indicating  a  tendency  for  
younger  respondents  to  possibly  overestimate  their  knowledge  of  alternative  therapies.  
This  tendency  has  critical  importance  regarding  the  hypothetical  clinical  implementation  of  
hallucinogens,  given  the  potential  for  young,  zealous  physicians  to  overestimate  their  
knowledge  of  hallucinogens’  clinical  effects–  the  very  scenario  which  largely  led  to  a  multi-­‐
national  moratorium  on  hallucinogen  research  in  the  mid-­‐20th  Century.  Therefore,  
establishing  an  objective  set  of  scientifically-­‐sound  research  and  educational  protocols  
regarding  the  management  of  MC  and  hallucinogens  will  be  imperative  for  mitigating  any  
potential  barriers  which  might  arise  between  more  orthodox,  senior  clinicians  and  younger,  
more  progressive  clinicians  as  alternative  therapies  continue  to  augment  the  standard  
medical  canon.    
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Conclusion:    
   This  systematic  review  provided  a  multi-­‐variate  analysis  of  the  existing  literature  on  
medical  professionals’  and  students’  attitudes  and  knowledge  regarding  medicinal  cannabis  
(MC)  to  assess  any  relevant  and  significant  trends  which  might  also  be  useful  in  forecasting  
analogous  trends  in  the  nascent  clinical  acceptance  of  hallucinogens.  It  was  found  that  both  
medical  students’  and  professionals’  support  for  the  legalization  of  MC  has  significantly  
increased  over  the  last  several  decades.  Additionally,  respondents’  desire  for  more  
educational  material  on  MC  and  respondents’  concerns  regarding  MC’s  potential  to  cause  
dependence  and  addiction  showed  a  ceiling  effect,  with  respondents  consistently  reporting  
a  high  level  of  desire  for  more  educational  material  and  a  high  level  of  concern  regarding  
MC’s  addictive  potential,  but  with  no  significant  changes  over  time.  These  findings  indicate  
that  clinicians  from  around  the  world  are  increasingly  accepting  of  alternative  and  formerly  
stigmatized  therapies,  but  there  is  also  a  strong  and  longstanding  desire  for  more  
knowledge  and  educational  material  regarding  these  novel  therapies.  Hence,  results  from  
this  systematic  review  should  encourage  the  medical  community  to  more  seriously  consider  
honest  and  comprehensive  investigations  into  these  (formerly)  socio-­‐politically  stigmatized  
therapies  to  allow  for  their  safe  and  effective  potential  integration  into  generally  accepted  
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